Today, emerging markets face a complex double burden of disease where the rapid surge of noncommunicable diseases, or NCDs, directly threatens macroeconomic resilience and human capital. Striking populations in their peak productive years, NCDs turn manageable health events into structural economic drags. For example, in Nigeria, HER2-positive breast cancer alone risks $1.39 billion in lost workforce productivity by 2027, according to data analyzed by the Wifor Institute and shared by Roche Africa. Behind this fiscal drag is a human bottleneck: Protracted diagnostic journeys averaging six months cause patients to present at noncurative stages. All this is happening against the backdrop of health systems typically designed for infectious diseases. But as countries navigate the post-COVID-19 era, traditional models of service delivery and financing no longer suffice. Innovative, context-specific, and integrated approaches are required. Addressing this evolving landscape requires resolving a structural mismatch: Either physical treatment infrastructure is expanded without concurrently ensuring patient demand; or insurance demand is expanded while local clinical delivery capacity is absent or remains limited. A pioneering multi-stakeholder coalition in Nigeria is deploying an innovative model under the umbrella of the country’s broader health reform agenda to test how sovereign wealth, development finance, national health authorities, and private industry can align to systematically address both sides of this equation simultaneously.

A new co-investment architecture for health infrastructure

That effort began in December 2023 when the Nigerian government launched an ambitious health sector reform program: the Nigeria Health Sector Renewal Investment Initiative. It aims to fast track the country’s universal health coverage, or UHC, aspirations and is largely driven by public financing agreed in a UHC compact signed by the federal and subnational governments. This provides leverage for mobilizing additional development assistance for health. However, recognizing that public resources alone will not be enough, the government began partnering with sovereign wealth, development finance institutions, and industry leaders to design a coordinated co-investment model that mobilizes private capital and stimulates patient demand. One area that could benefit from such investment is oncology. On the supply side, expanding specialized end-to-end oncology capacity requires capital-intensive investments anchored directly in national economic and health priorities. In Nigeria, a $154 million investment initiative — executed by the Nigeria Sovereign Investment Authority, or NSIA, through its health care subsidiary, MedServe, in partnership with the International Finance Corporation, or IFC — demonstrates how combining a sovereign mandate with international development finance and industry expertise creates a durable asset base specifically for cancer care. This joint venture relies on the distinct strengths of each institution. NSIA provides domestic equity, strategic national direction, and local execution expertise, ensuring infrastructure development directly advances national initiatives, such the Presidential Initiative for Unlocking the Healthcare Value Chains. Complementing this, the International Finance Corporation, applies rigorous risk-management frameworks, evaluating financial viability, operational resilience, and environmental and social standards while deploying tailored blended finance — including long-tenor concessional local currency structures — to insulate the capital model.